Majestic Research Finds Hematologists/Oncologists Expect To Change Multiple Myeloma Treatment Practices Due To ASH 2009 Data

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Blood / Hematology;  Cancer / Oncology
Article Date: 15 Jan 2010 - 15:00 PDT


In a study published by Majestic Research's Market Research Group (formerly Rood Research), it was found that many hematologists and oncologists who attended the American Society of Hematology (ASH) 2009 Annual Meeting expect to change their multiple myeloma treatment practices, based on new data presented at the meeting. Of the hematologists and oncologists surveyed, 43% reported they expect to change their typical treatment protocol as a result of the meeting, with most planning to use more of either Revlimid, Velcade, or the two agents together in combination.

MM-015, a Phase III Study on the continuous use of Revlimid with Melphalan and Prednisone, was the most recalled study from ASH for Revlimid, with 53% of hematologists and oncologists surveyed recalling the results. Overall aided response to the results was almost completely positive, and 94% of those surveyed expect MM-015 to have at least some impact on multiple myeloma treatment practices. Further, 80% believe the results of the MM-015 Study are significant enough to encourage continuous use of Revlimid in multiple myeloma. Majestic's analysis also concluded that combination use of Revlimid and Velcade for multiple myeloma will continue to rise in 2010. Jemma A. Lampkin, Assistant Director of Research, who manages the Event Pulse studies, said, "These findings are positive for Celgene, as they show the continuing potential of Revlimid in oncology. We expect Revlimid and Velcade use to stay strong in 2010, especially with the increased use of these agents in combination."

These findings were included in a study conducted by Majestic called Event Pulse: ASH 2009. Fielded immediately following the ASH meeting in December, Event Pulse also focused on responses to new non-Hodgkin's lymphoma data presented at the ASH meeting, as well as reactions to potential new agents for both multiple myeloma and NHL, including pomalidomide, carfilzomib, ofatumumab, and clofarabine. The multiple myeloma and non-Hodgkin's lymphoma reports became available for purchase on December 22, 2009. Majestic plans to continue the Event Pulse reports throughout the year, and will expand the reports into other therapeutic areas.

Event Pulse: ASH 2009 draws data from of a targeted Internet survey of 75 hematologists and oncologists who attended ASH 2009, two in-depth telephone discussions with key opinion leaders in oncology, an analysis of longitudinal data on 340+ NHL patients, and 8,800+ multiple myeloma patients from a nationwide network of 800+ oncology clinics, and an analysis of daily treatment decisions from a panel of 425 oncologists and hematologists spanning 2005-2009.

About Event Pulse

Event Pulse is a syndicated report series that evaluates the impact of market events on physician treatment practices. These report series provide information on how changes such as new products, data, or guidelines fit into the treatment algorithm, impact current therapies, and change market dynamics.

Source
Majestic Research

• Additional
• References
• Citations